Fig. 2.

T- and NK-cell characteristics before and during aPD-1/CTLA-4 combination therapy

(a, b, c, d) Percentage of T-and NK-cell subsets (a), CD4 T-cell subsets (b), Treg subsets (c) and CD8 T-cells subsets (d) respectively, at screening and on-treatment time points. (e, f, g) Percentage of Ki67⁺ CD 4 T-cell subsets, (TCM p = 0.003, TEM p = 0.007, TEMRA p = 0.028) (e), Tregs subsets (f) and CD8 T-cell subsets (TN p = 0.036, TCM p = 0.03,) (g) respectively, at screening and on-treatment time points. (h, i, j) Comparison between responding (R) and non-responding (NR) patients for the percentage of Ki67⁺ CD 4 T-cell subsets (TCM R p = 0.01, TCM NR p = 0.04, TEM R p = 0.01) (h), Tregs subsets (i) and CD8 T-cell subsets (j) respectively, at screening and on-treatment time points. Paired samples are shown connected by black lines in each graph. Significance (Wilcoxon signed-rank test for paired analysis of screening and on-treatment samples and Mann–Whitney U test for comparison of response groups) is shown in each graph, with * p < 0.05 and ** p < 0.01. P values were corrected for multiple testing, using the Benjamini and Hochberg False Discovery Rate.